EEF1A2 and ovarian cancer: A pentavalent vaccine formed by two glycolipids (Globo-H and GM2) and three short O-glycans (Tn, sTn and Core 1 structure) linked to KLM was found to be able to induce a serological response in ovarian cancer patients after a Phase I trial [135].